Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake

American Journal of Physiology - Endocrinology and Metabolism

Volumn 305, Issue 9, 2013, Pages

  McNelis, Joanne C ^a   Manolopoulos, Konstantinos N ^a   Gathercole, Laura L ^a   Bujalska, Iwona J ^a   Stewart, Paul M ^a   Tomlinson, Jeremy W ^a   Arlt, Wiebke ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Dehydroepiandrosterone; Human adipogenesis; Insulin sensitivity

Indexed keywords

CORTISONE; GLUCOCORTICOID ANTAGONIST; GLUCOSE; PRASTERONE; ROSIGLITAZONE;

ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE;

11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1; DEHYDROEPIANDROSTERONE; HUMAN ADIPOGENESIS; INSULIN SENSITIVITY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOCYTES; ADIPOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COLORIMETRY; DEHYDROEPIANDROSTERONE; DNA PRIMERS; GLUCOCORTICOIDS; GLUCOSE; HUMANS; RNA, MESSENGER; THYMIDINE;

EID: 84886997219     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00314.2012     Document Type: Article

References (48)

1. Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 288: E957-E964, 2005.
2. Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 288: E957-E964, 2005.
3. Bader T, Zoumakis E, Friedberg M, Hiroi N, Chrousos GP, Hochberg Z. Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes. Horm Metab Res 34: 752-757, 2002.
4. Bélanger C, Hould FS, Lebel S, Biron S, Brochu G, Tchernof A. Omental and subcutaneous adipose tissue steroid levels in obese men. Steroids 71: 674-682, 2006.
5. Bujalska IJ, Draper N, Michailidou Z, Tomlinson JW, White PC, Chapman KE, Walker EA, Stewart PM. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1. J Mol Endocrinol 34: 675-684, 2005.
6. Bujalska IJ, Gathercole LL, Tomlinson JW, Darimont C, Ermolieff J, Fanjul AN, Rejto PA, Stewart PM. A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol 197: 297-307, 2008.
7. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology 140: 3188-3196, 1999.
8. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96: 632-642, 2011.
9. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes 10: 193-204, 1986.
10. Coleman DL. Therapeutic effects of dehydroepiandrosterone (DHEA) and its metabolites in obese-hyperglycemic mutant mice. Prog Clin Biol Res 265: 161-175, 1988.
11. Coleman DL, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31: 830-833, 1982.
12. Cooper MS, Stewart PM. 11beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 94: 4645-4654, 2009.
13. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 12: 722-734, 2011.
14. Darimont C, Zbinden I, Avanti O, Leone-Vautravers P, Giusti V, Burckhardt P, Pfeifer AM, Macé K. Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization. Cell Death Differ 10: 1025-1031, 2003.
15. Digby JE, Montague CT, Sewter CP, Sanders L, Wilkison WO, O'Rahilly S, Prins JB. Thiazolidinedione exposure increases the expres-sion of uncoupling protein 1 in cultured human preadipocytes. Diabetes 47: 138-141, 1998.
16. Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 4: 377-385, 2005.
17. Feher T, Bodrogi L. A comparative study of steroid concentrations in human adipose tissue and the peripheral circulation. Clin Chim Acta 126: 135-141, 1982.
18. Fujioka K, Kajita K, Wu Z, Hanamoto T, Ikeda T, Mori I, Okada H, Yamauchi M, Uno Y, Morita H, Nagano I, Takahashi Y, Ishizuka T. Dehydroepiandrosterone reduces preadipocyte proliferation via androgen receptor. Am J Physiol Endocrinol Metab 302: E694-E704, 2012.
19. Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW. Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J Clin Endocrinol Metab 91: 4332-4339, 2007.
20. Gordon GB, Shantz LM, Talalay P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul 26: 355-382, 1987.
21. Grégoire F, Genart C, Hauser N, Remacle C. Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp Cell Res 196: 270-278, 1991.
22. Gu S, Ripp SL, Prough RA, Geoghegan TE. Dehydroepiandrosterone affects the expression of multiple genes in rat liver including 11betahydroxysteroid dehydrogenase type 1: a cDNA array analysis. Mol Pharmacol 63: 722-731, 2003.
23. Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, Pfeiffer EF. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 84: 1663-1670, 1989.
24. Hauner H, Schmid P, Pfeiffer EF. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab 64: 832-835, 1987.
25. Hewitt KN, Walker EA, Stewart PM. Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity. Endocrinology 146: 2539-2543, 2005.
26. Kajita K, Ishizuka T, Miura A, Ishizawa M, Kanoh Y, Yasuda K. The role of atypical and conventional PKC in dehydroepiandrosterone-induced glucose uptake and dexamethasone-induced insulin resistance. Biochem Biophys Res Commun 277: 361-367, 2000.
27. Kajita K, Ishizuka T, Miura A, Kanoh Y, Ishizawa M, Kimura M, Muto N, Yasuda K. Glucocorticoid-induced insulin resistance associates with activation of protein kinase C isoforms. Cell Signal 13: 169-175, 2001.
28. Kajita K, Ishizuka T, Mune T, Miura A, Ishizawa M, Kanoh Y, Kawai Y, Natsume Y, Yasuda K. Dehydroepiandrosterone down-regulates the expression of peroxisome proliferator-activated receptor gamma in adipocytes. Endocrinology 144: 253-259, 2003.
29. Kajita K, Ishizuka T, Mune T, Miura A, Ishizawa M, Kanoh Y, Kawai Y, Natsume Y, Yasuda K. Dehydroepiandrosterone down-regulates the expression of peroxisome proliferator-activated receptor gamma in adipocytes. Endocrinology 144: 253-259, 2003.
30. Kawai Y, Ishizuka T, Kajita K, Miura A, Ishizawa M, Natsume Y, Uno Y, Morita H, Yasuda K. Inhibition of PKCbeta improves glucocorticoid-induced insulin resistance in rat adipocytes. IUBMB Life 54: 365-370, 2002.
31. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94: 14924-14929, 1997.
32. Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone-sulfate (DHEAS) reduces adipocyte hyperplasia associated with feeding rats a high-fat diet. Int J Obes Relat Metab Disord 21: 1058-1064, 1997.
33. Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone reduces proliferation and differentiation of 3T3-L1 preadipocytes. Biochem Biophys Res Commun 30: 479-504, 1998.
34. Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone reduces proliferation and differentiation of 3T3-L1 preadipocytes. Biochem Biophys Res Commun 248: 497-504, 1998.
35. Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 69: 279-289, 2004.
36. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170, 2001.
37. Perrini S, Natalicchio A, Laviola L, Belsanti G, Montrone C, Cignarelli A, Minielli V, Grano M, De Pergola G, Giorgino R, Giorgino F. Dehydroepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes 53: 41-52, 2004.
38. Radford DJ, Wang K, McNelis JC, Taylor AE, Hechenberger G, Hofmann J, Chahal H, Arlt W, Lord JM. Dehdyroepiandrosterone sulfate directly activates protein kinase C-beta to increase human neutrophil superoxide generation. Mol Endocrinol 24: 813-821, 2010.
39. Rice SP, Zhang L, Grennan-Jones F, Agarwal N, Lewis MD, Rees DA, Ludgate M. Dehydroepiandrosterone (DHEA) treatment in vitro inhibits adipogenesis in human omental but not subcutaneous adipose tissue. Mol Cell Endocrinol 320: 51-57, 2010.
40. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33: 1516-1522, 2010.
41. Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, Fukushima Y, Onishi Y, Ono H, Fujishiro M, Kikuchi M, Oka Y, Asano T. Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 49: 1700-1708, 2000.
42. Stewart PM, Tomlinson JW. Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both? Diabetes 58: 14-15, 2009.
43. Tagawa N, Minamitani E, Yamaguchi Y, Kobayashi Y. Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11beta-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue. Steroids 76: 1546-1553, 2011.
44. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151: 1-14, 2004.
45. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25: 831-866, 2004.
46. Turnbow MA, Keller SR, Rice KM, Garner CW. Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J Biol Chem 269: 2516-2520, 1994.
47. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292: 2243-2248, 2004.
48. Wolf G. The molecular mechanism of the stimulation of adipocyte differentiation by a glucocorticoid. Nutr Rev 57: 324-326, 1999.